Drug General Information
Drug ID	D06RLU
Former ID	DNCL003692
Drug Name	ACT-128800
Drug Type	Small molecular drug
Indication	Psoriasis [ICD9: 696; ICD10:L40]		Phase 2	[522598]
Company	Actelion
Structure		Download 2D MOL 3D MOL
Formula	C23H25ClN2O4S
PubChem Compound ID	11224984
Target and Pathway
Target(s)	Sphingosine 1-phosphate receptor 1	Target Info	Modulator	[543701]
KEGG Pathway	FoxO signaling pathway
	Sphingolipid signaling pathway
	Neuroactive ligand-receptor interaction
NetPath Pathway	IL4 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	IL2 Signaling Pathway
Pathway Interaction Database	Fc-epsilon receptor I signaling in mast cells
	S1P3 pathway
	S1P1 pathway
	Sphingosine 1-phosphate (S1P) pathway
	PDGFR-beta signaling pathway
Reactome	G alpha (i) signalling events
	Lysosphingolipid and LPA receptors
WikiPathways	Signal Transduction of S1P Receptor
	Small Ligand GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 522598	ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.
Ref 543701	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.